ProCE Banner Activity

Treating Patients With FLT3-Mutated Acute Myeloid Leukemia

Slideset Download
Conference Coverage
Download this slideset from a live ASH symposium reviewing the latest treatment approaches, including newly approved agents, for patients with FLT3-mutated AML.

Released: December 04, 2018

Expiration: December 03, 2019

No longer available for credit.

Share

Faculty

Mark J. Levis

Mark J. Levis, MD, PhD

Professor of Oncology
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Actinium

Astellas Text

Boston Biomedical

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Mark J. Levis, MD, PhD

Professor of Oncology
Division of Hematologic Malignancies
Department of Oncology
Johns Hopkins University
Director, Adult Leukemia Service
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland